// App-Quantinova.ai

POS1497-PARE (2021) : POST-TRIAL SURVEY OF PARTICIPANTS OF A PHASE 3 CLINICAL TRIAL IN SSC-ILD

Researchers

Presenter

  • I. Galetti

Principal Investigators

  • E. Brown

  • A. Kennedy

  • R. J. Riggs

  • A. Roennow

  • M. Sauv

  • J. Welling

  • H. Finnern

  • A. Gilbert

  • M. Gahlemann

  • W. Sauter

Medical Centers

  • Gruppo Italiano per la Lotta alla Sclerodermia, GILS, Milano, Italy

  • FESCA aisbl, n/a, Saint Maur, Belgium

  • Scleroderma and Raynaud’s UK, London, United Kingdom

  • Scleroderma Foundation, Inc, n/a, Danvers, United States of America

  • Sklerodermiforeningen, Rødovre, Denmark

  • Scleroderma Canada, Hamilton, Canada

  • Nationale Vereniging Voorlupus, APS, Sclerodermie en MCTD, n/a, UTRECHT, Netherlands

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • AK Gilbert Ltd, n/a, Brighton, United Kingdom

  • Boehringer Ingelheim (Schweiz), GmbH, Basel, Switzerland,

  • Boehringer Ingelheim International GmbH, Biberach, Germany

Locations

  • Italy

  • Belgium

  • United Kingdom

  • United States

  • Denmark

  • Canada

  • Netherlands

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved